Literature DB >> 10997830

The incidence of cytomegalovirus (CMV) antigenemia and CMV disease is reduced by highly active antiretroviral therapy.

S Varani1, P Spezzacatena, R Manfredi, F Chiodo, A Mastroianni, P Ballarini, A Boschini, T Lazzarotto, M P Landini.   

Abstract

Cytomegalovirus (CMV) infection was one of the most common opportunistic infections in AIDS patients, leading to blindness or life-threatening disease in about 40% of patients in the later stages of AIDS before highly active antiretroviral therapy (HAART). In a retrospective multicenter study we investigated the incidence of CMV retinitis and organ involvement in Northern Italy before (1995 and 1996) and after the introduction of HAART (1997 and 1998) as well as the data regarding CMV antigenemia. We found a sharp drop in the incidence of CMV disease in AIDS patients as well as a decline in the incidence of relapses of CMV-disease after the widespread introduction of HAART. Moreover, there was a decrease in the incidence of antigenemia-positive cases in AIDS patients in the era of HAART and the median CMV viral load was significantly higher in patients who didn't receive HAART than in patients who received HAART (p = 0.001, t test).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10997830     DOI: 10.1023/a:1007619323939

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  24 in total

1.  Sharp drop in the prevalence of human cytomegalovirus leuko-DNAemia in HIV-infected patients following highly active antiretroviral therapy.

Authors:  G Gerna; A d'Arminio Monforte; M Zavattoni; A Sarasini; L Testa; M G Revello; M Moroni
Journal:  AIDS       Date:  1998-01-01       Impact factor: 4.177

2.  Quantitative cytomegalovirus (CMV) antigenaemia during antiviral treatment of AIDS-related CMV disease.

Authors:  R Manfredi; T Lazzarotto; P Spezzacatena; P Dal Monte; A Mastroianni; O V Coronado; F Chiodo
Journal:  J Antimicrob Chemother       Date:  1997-08       Impact factor: 5.790

3.  Therapeutic effect of combination antiretroviral therapy on cytomegalovirus retinitis.

Authors:  S M Whitcup; E Fortin; R B Nussenblatt; M A Polis; C Muccioli; R Belfort
Journal:  JAMA       Date:  1997-05-21       Impact factor: 56.272

4.  Development of cytomegalovirus (CMV) disease may be predicted in HIV-infected patients by CMV polymerase chain reaction and the antigenemia test.

Authors:  K K Dodt; P H Jacobsen; B Hofmann; C Meyer; H J Kolmos; P Skinhøj; B Norrild; L Mathiesen
Journal:  AIDS       Date:  1997-03       Impact factor: 4.177

5.  Use of a quantitative cytomegalovirus (CMV) antigenemia test in evaluating HIV+ patients with and without CMV disease.

Authors:  P E Wetherill; M L Landry; P Alcabes; G Friedland
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1996-05-01

6.  The use of combination antiretroviral therapy in HIV-infected patients.

Authors:  C D Holtzer; M Roland
Journal:  Ann Pharmacother       Date:  1999-02       Impact factor: 3.154

7.  Decrease of cytomegalovirus replication in human immunodeficiency virus infected-patients after treatment with highly active antiretroviral therapy.

Authors:  C E O'Sullivan; W L Drew; D J McMullen; R Miner; J Y Lee; R A Kaslow; J G Lazar; M S Saag
Journal:  J Infect Dis       Date:  1999-09       Impact factor: 5.226

8.  Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes.

Authors:  W van der Bij; R Torensma; W J van Son; J Anema; J Schirm; A M Tegzess; T H The
Journal:  J Med Virol       Date:  1988-06       Impact factor: 2.327

9.  Quantitation of human cytomegalovirus DNA from peripheral blood cells of human immunodeficiency virus-infected patients could predict cytomegalovirus retinitis.

Authors:  L Rasmussen; S Morris; D Zipeto; J Fessel; R Wolitz; A Dowling; T C Merigan
Journal:  J Infect Dis       Date:  1995-01       Impact factor: 5.226

Review 10.  Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel.

Authors:  C C Carpenter; M A Fischl; S M Hammer; M S Hirsch; D M Jacobsen; D A Katzenstein; J S Montaner; D D Richman; M S Saag; R T Schooley; M A Thompson; S Vella; P G Yeni; P A Volberding
Journal:  JAMA       Date:  1998-07-01       Impact factor: 56.272

View more
  5 in total

1.  Incremental cost effectiveness of prophylaxis for cytomegalovirus disease in patients with AIDS.

Authors:  J H Kempen; K D Frick; D A Jabs
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

2.  Retinal and extraocular cytomegalovirus end-organ disease in HIV-infected patients in Europe: a EuroSIDA study, 1994-2001.

Authors:  I Yust; Z Fox; M Burke; A Johnson; D Turner; A Mocroft; C Katlama; B Ledergerber; P Reiss; O Kirk
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-06-30       Impact factor: 3.267

3.  Risk of cataract among subjects with acquired immune deficiency syndrome free of ocular opportunistic infections.

Authors:  John H Kempen; Elizabeth A Sugar; Rohit Varma; James P Dunn; Murk-Hein Heinemann; Douglas A Jabs; Alice T Lyon; Richard A Lewis
Journal:  Ophthalmology       Date:  2014-08-08       Impact factor: 12.079

Review 4.  Ocular herpes: the pathophysiology, management and treatment of herpetic eye diseases.

Authors:  Lucy Zhu; Hua Zhu
Journal:  Virol Sin       Date:  2014-12-15       Impact factor: 4.327

Review 5.  Development and Clinical Translation of Approved Gene Therapy Products for Genetic Disorders.

Authors:  Alireza Shahryari; Marie Saghaeian Jazi; Saeed Mohammadi; Hadi Razavi Nikoo; Zahra Nazari; Elaheh Sadat Hosseini; Ingo Burtscher; Seyed Javad Mowla; Heiko Lickert
Journal:  Front Genet       Date:  2019-09-25       Impact factor: 4.599

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.